Recent Updates — NLSPW

NewcelX Ltd. entered into definitive securities purchase agreements for a private placement offering with accredited investors on July 31, 2026. The company agreed to sell 347,134 common shares or pre-funded warrants at $4.033 per share, along with common warrants to purchase an equal number of shares at an exercise price of $4.437. The offering is expected to generate gross proceeds of approximately $1.4 million, with potential additional proceeds of $1.5 million upon full warrant exercise. Closing is anticipated on or about August 14, 2026. Proceeds will advance NCEL-101 for Type 1 Diabetes in collaboration with Eledon Pharmaceuticals and support working capital. The company operates in the biotechnology industry, focusing on drug development.

NewcelX Ltd. announced the pricing of a $1.4 million private equity financing on July 31, 2026. The company sold 347,134 common shares at $4.033 per share, representing a 20% premium to the previous closing price, alongside warrants for an equal number of shares at $4.437. Proceeds will advance NCEL-101, its lead type 1 diabetes program, and support working capital. The transaction is expected to close around August 14, 2026. NewcelX Ltd. operates in the biopharmaceutical industry, developing stem cell-based therapies for type 1 diabetes.

NewcelX Ltd. announced on July 15, 2026, that it has been granted a patent in Brazil for NCEL-101, a treatment for Type 1 diabetes. This patent grant expands the company's global intellectual property portfolio. NewcelX Ltd. is a biotechnology company focused on developing therapeutic treatments.

On July 8, 2026, NewcelX Ltd. announced the appointment of Dr. Camillo Ricordi, a specialist in diabetes cure research, to its Scientific Advisory Board. This appointment is intended to support the company's scientific initiatives. NewcelX Ltd. is a biotechnology company focused on developing treatments for diabetes.